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Background: The isopentenols, including isoprenol and prenol, are excellent alternative fuels. However, they are
not compounds largely accumulated in natural organism. The need for the next generation of biofuels with better
physical and chemical properties impels us to develop biosynthetic routes for the production of isoprenol and
prenol from renewable sugar. In this study, we use the heterogenous mevalonate-dependent (MVA) isoprenoid
pathway for the synthesis of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP)
intermediates, and then convert IPP and DMAPP to isoprenol and prenol, respectively.
Results: A mevalonate titer of 1.7 g/L was obtained by constructing an efficient MVA upper pathway in engineered
E. coli. Different phosphatases and pyrophosphatases were investigated for their abilities in hydrolyzing the IPP and
DMAPP. Consequently, ADP-ribose pyrophosphatase was found to be an efficient IPP and DMAPP hydrolase.
Moreover, ADP-ribose pyrophosphatase from Bacillus subtilis (BsNudF) exhibited a equivalent substrate specificity
towards IPP and DMAPP, while ADP-ribose pyrophosphatase from E. coli (EcNudF) presented a high substrate
preference for DMAPP. Without the expression of any phosphatases or pyrophosphatases, a background level of
isopentenols was synthesized. When the endogenous pyrophosphatase genes (EcNudF and yggV) that were capable
of enhancing the hydrolyzation of the IPP and DMAPP were knocked out, the background level of isopentenols
was still obtained. Maybe the synthesized IPP and DMAPP were hydrolyzed by some unknown hydrolases of E. coli.
Finally, 1.3 g/L single isoprenol was obtained by blocking the conversion of IPP to DMAPP and employing the
BsNudF, and 0.2 g/L ~80% prenol was produced by employing the EcNudF. A maximal yield of 12% was achieved
in both isoprenol and prenol producing strains.
Conclusions: To the best of our knowledge, this is the first successful report on high-specificity production of
isoprenol and prenol by microbial fermentation. Over 1.3 g/L isoprenol achieved in shake-flask experiments
represents a quite encouraging titer of higher alcohols. In addition, the substrate specificities of ADP-ribose
pyrophosphatases were determined and successfully applied for the high-specificity synthesis of isoprenol and
prenol. Altogether, this work presents a promising strategy for high-specificity production of two excellent biofuels,
isoprenol and prenol.
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With increasing concerns about environmental problems
and energy security, research interest has been aroused in
the field of microbial production of fuels and chemicals
from renewable sources [1-4]. Short chain alcohols (C2-
C5) represent a category of primary biofuels. Compared
with the ethanol (C2), a main biofuel in use today [5], the
C5 alcohols have higher energy density and lower water
miscibility [1,6]. Moreover, the branched-chain unsatu-
rated isopentenols (isoprenol and prenol) possess higher
octane numbers and better low-temperature fluidity than
their straight-chain saturated counterpart. In addition, by
removing a molecule of water, isoprenol can be converted
to isoprene, a very important monomer for synthesizing
rubber. Global rubber demand is forecast to reach 27.2
million metric tons in 2012. Prenol is also of great import-
ance as a building block to synthesize pyrethroid, a widely
used pesticide. However, the isoprenol and prenol, which
are conventionally manufactured from petroleum-derived
isobutene and formaldehyde, are not compounds largely
accumulated in natural organism. The need for the next
generation of biofuels with better physical and chemical
properties impels us to seek a biological route for direct
production of isopentenols from renewable sugar in a mi-
crobial fermentation process.
To obtain the C5 backbones, we paid attention to the iso-
prenoid biosynthetic pathways, which exist as mevalonate-
dependent (MVA) isoprenoid pathway in eukaryotes or
deoxyxylulose 5-phosphate (DXP) pathway in plants andFigure 1 Isoprenol and prenol biosynthesis pathway. The heterogenou
The black arrow represents the MVA upper pathway, the blue arrow repres
isopentenol forming pathway. HMG-CoA, 3-hydroxy-3-methylglutaryl-coenz
mevalonate kinase; MKK, phosphomevalonate kinase; MVD, mevalonate pyr
dimethylallyl pyrophosphate isomerase.most prokaryotes [7]. The MVA and DXP pathways both
end with the synthesis of isopentenyl pyrophosphate (IPP)
and dimethylallyl pyrophosphate (DMAPP), which are used
as the C5 building blocks for preparing isoprenoids in vivo
[7-10]. Expression of the heterologous MVA pathway can
avoid the unknown physiological control elements in E. coli
and thus result in a high-level production of isoprenoid
precursors [7]. Therefore, we took advantage of the MVA
pathways for enhanced production of the precursors, IPP
and DMAPP. The intermediates IPP and DMAPP can be
finally converted to isoprenol and prenol by removing their
pyrophosphates (Figure 1).
The recovery of the desired products will be greatly sim-
plified if the single isoprenol or prenol can be harvested in
the culture. However, thus far, no study has been carried
out for high-specificity production of isoprenol and prenol
in either wild-type or engineered microbes. To reach this
goal, firstly, it is needed to employ phosphatases or pyro-
phosphatases with appropriate substrate specificities.
Secondly, it is also needed to adjust the carbon flux into
IPP and DMAPP, which can be interconverted with the
help of isopentenyl pyrophosphate isomerase [11]. But
unfortunately, no such efforts were made to tailor the
composition of the isopentenols.
In this study, we devised a biosynthetic approach to
selectively produce isoprenol and prenol in engineered
E. coli. To improve the production of isoprenol and
prenol, we compared the efficacies of different phospha-
tases and pyrophosphatases, and selectively directed thes pathway that was introduced into E. coli is indicated by the red line.
ents the MVA lower pathway, and the purple arrow represents the
yme A; HMGS, HMG-CoA synthase; HMGR, HMG-CoA reductase; MK,
ophosphate decarboxylase; IDI, isopentenyl pyrophosphate:
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tion of the heterogenous isopentenyl pyrophosphate isom-
erase or overexpression of a selective pyrophosphatase. We
also discussed the effect of different pyrophosphatases on
the hydrolyzation of IPP and DMAPP.
Results
Enhanced production of mevalonate
The MVA pathway can be divided into upper pathway
and lower pathway, which are connected by mevalonate
(Figure 1). To convert glucose to mevalonate, it is needed
to introduce the exogenous HMG-CoA synthase and
HMG-CoA reductase into the E. coli cell. We first
expressed the HMG-CoA synthase (HMGS) and the trun-
cated HMG-CoA reductase (tHMGR) from Saccharomy-
ces cerevisiae [12], but the resultant engineered strain only
produced 36.7 mg/L mevalonate. Tabata and Hashimoto
improved the production of mevalonate by expressing a
mevalonate pathway derived from Enterococcus faecalis
[13]. To further enhance the synthesis of mevalonate in
our study, we next employed the mvaS and mvaE from
E. faecalis as the HMG-CoA synthase and HMG-CoA
reductase, respectively. The yielded strain had a 45-fold
increase in mevalonate accumulation, reaching a titer of
1.7 g/L. The improved mevalonate production may be
attributed to the additional acetyl-CoA acetyltransferase
activity of MvaE, which can promote the conversion of
acetyl-CoA to acetoacetyl-CoA [14].Figure 2 Isoprenol and prenol production by employing different ph
S. cerevisiae isopentenyl pyrophosphate:dimethylallyl pyrophosphate isome
type E. coli BL21(DE3); Control, without the overexpression of any phosphat
coli; ‘DPP1 and ‘LPP1, phosphatase genes ‘DPP1 and ‘LPP1 from S. cerevisiae;
pyrophosphatase gene from B. subtilis; EcNudF, the ADP-ribose pyrophosph
independent experiments.High-specificity production of isoprenol and prenol
The conversion of mevalonate to IPP and DMAPP re-
quires four steps, sequentially catalyzed by mevalonate
kinase, phosphomevalonate kinase, mevalonate pyro-
phosphate decarboxylase and isopentenyl pyrophosphate:
dimethylallyl pyrophosphate isomerase, whose coding
genes in S. cerevisiae S288c are ERG12, ERG8, ERG19 and
IDI1, respectively [15-18]. We cloned the four genes of S.
cerevisiae into the pTrcHis2B to generate pTrcLower ex-
pression vector, with a method of successive hybridization
[19]. Expression of the whole MVA pathway in E. coli
(control strain) resulted in 4.6 mg/L isoprenol and
16.2 mg/L prenol (Figure 2a, Control).
The low level of isopentenol production is probably at-
tributed to the poor phosphatase or pyrophosphatase
activity in E. coli. Therefore, it is needed to overexpress
phosphatase or pyrophosphatase that can efficiently
hydrolyze the phosphoester bond of IPP or DMAPP.
Phosphatases DPP1 and LPP1 from S. cerevisiae were
found to be able to promote the production of geranyl-
geraniol by removing the pyrophosphatases of geranyl-
geranyl diphosphate [20]. The alkaline phosphatase is a
nonspecific phosphomonoesterase that can remove the
inorganic phosphate to release corresponding alcohols
[21]. It is possible that these phosphatases also have cata-
lytic activities towards IPP and DMAPP. So we tested the
efficiencies of the phosphatases ‘PhoA (a leaderless version
of PhoA) from E. coli, ‘DPP1 (a leaderless version of DPP1)osphatases and pyrophosphatases. a, strains with the expression of
rase gene IDI1; b, strains without the expression of IDI1. BL21, the wild-
ase or pyrophosphatase gene; ‘phoA, phosphatase gene ‘phoA from E.
phoE, phosphatase gene from B. subtilis; BsNudF, the ADP-ribose
atase gene from E. coli. The error bars represent the range from three
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S. cerevisiae and PhoE from B. subtilis on the production of
isopentenols. The engineered strains employing the four
phosphatases still only produced the background level of
isopentenols (Figure 2, ‘phoA, ‘DPP1, ‘LPP1 and phoE),
suggesting that these phosphatases can not efficiently re-
move the pyrophosphates of IPP and DMAPP.
So we further introduced the ADP-ribose pyrophos-
phatase gene from B. subtilis (BsNudF) into the strain that
employed the whole MVA pathway [22]. The resultant
BsNudF expressing strain dramatically enhanced the syn-
thesis of isoprenol and prenol (Figure 2a, BsNudF). This
result demonstrates that the ADP-ribose pyrophosphatase
is a good candidate biocatalyst to remove the pyrophos-
phate from IPP and DMAPP.
We noticed that expression of BsNudF with the whole
MVA pathway (YY158) yielded a blend of isoprenol and
prenol in the ratio of ~1:1 (Figure 2a, BsNudF), suggesting
that BsNudF has high affinity for both IPP and DMAPP.
The recovery of the desired products will be greatly sim-
plified if the single isoprenol or prenol can be harvested in
the culture. It is needed for us to tailor the composition of
the products by further metabolic engineering. To obtain
a single isoprenol, we blocked the conversion of IPP to
DMAPP by deleting the IDI1 gene of the pTrcLower.
Indeed, the strains without the expression of IDI1 synthe-
sized the isoprenol as their single product (Figure 2b). Fi-
nally, an engineered strain expressing BsNudF and partial
MVA pathway (YY159) produced 1,337 mg/L isoprenol in
shake flask, with prenol nearly undetected (Figure 2b,
BsNudF; Figure 3). This result demonstrates that the
metabolic flux of IPP to DMAPP was successfully blocked,
and nearly all synthesized IPP entered the isoprenol bio-
synthetic pathway, contributing to the greatly improved
isoprenol production.
To raise the specificity for prenol production, it is
needed to find a pyrophosphatase that has a higher
substrate preference towards DMAPP. As above men-
tioned, the strain without expression of any phosphatase
and pyrophosphatase produced 20.8 mg/L isoprenol and
prenol, with the main contribution coming from prenol
(Figure 2a, Control). This result suggests some endogen-
ous pyrophosphatase of E. coli probably contributed to
the background level of isopentenols, given the expre-
ssion of phosphatase didn’t exhibit any enhanced pro-
duction of isopentenols. In addition, expression of
ADP-ribose pyrophosphatase from B. subtilis (BsNudF)
greatly enhanced the production of isopentenols as afore-
mentioned. Therefore, we paid attention to the ADP-
ribose pyrophosphatase of E. coli (encoded by EcNudF
gene). By overexpressing the EcNudF and the entire MVA
pathway (YY168), 0.2 g/L isopentenols were finally
achieved, with prenol accounting for over 80% (Figure 2a,
EcNudF; Figure 3).Knockout of the endogenous pyrophosphatase genes of
E. coli
As above mentioned, isopentenols can be synthesized
in small amounts even if no pyrophosphatase was
overexpressed. We speculated the ADP-ribose pyrophos-
phatases of E. coli (EcNudF) contributed to the back-
ground level of isopentenols, given the overexpression of
EcNudF notably enhanced the production of isopen-
tenols. However, when the endogenous EcNudF gene of
E. coli was knocked out, the background level of isopen-
tenols was still observed.
To test if other pyrophosphatases are also capable
of hydrolyzing the IPP and DMAPP, we overexpressed
E. coli NADH pyrophosphatase (nudC), dITP/XTP
pyrophosphatase (yggV), UDP-2,3-diacylglucosamine
pyrophosphatase (lpxH), phosphoribosyl-ATP pyro-
phosphatase (hisl), inorganic pyrophosphatase (ppa)
and CDP-diacylglycerol pyrophosphatase (cdh) in ISP2148
strain, respectively. Overexpression of yggV improved the
isopentenols to some extent, while overexpression of other
pyrophosphatases did not enhance the production of
isopentenols (Figure 4). It demonstrates that dITP/XTP
pyrophosphatase is also able to hydrolyze the pyrophos-
phates of IPP and DMAPP.
We further deleted the yggV gene in the EcNudF gene
knockout mutant, yielding a EcNudF-yggV double-gene
knockout mutant. However, expression of the MVA
pathway in this double-gene knockout mutant still syn-
thesized a background level of isopentenols. To check if
the background level of isopentenols was produced by
the spontaneous hydrolysis of IPP and DMAPP, we de-
termined the IPP and DMAPP hydrolysis in an enzyme-
free solution. However, no isopentenols was formed after
incubating the solution for the same time as the shake-
flask experiment. Therefore, it is speculated that some
unknown E. coli hydrolases resulted in the background
level of isopentenols.
Effect of mevalonate accumulation on the production of
isopentenols
It has been known that mevalonate is an important inter-
mediate in the isopentenol biosynthetic pathways. The
isopentenol production may be further improved by accel-
erating the synthesis of mevalonate. It was found that the
native HMG-CoA synthase MvaS had a non-optimal cata-
lytic efficiency. When the Ala-110 of the MvaS was re-
placed by glycine, the mutated enzyme MvaSA110G
achieved a 140-fold increase in overall reaction rate [23]. In
addition, the biosynthesis of isoprenoid compounds was
found to be proportional to the amount of mevalonate, up
to a concentration of over 5 g/L mevalonate [7].
Therefore, we substituted the MvaS with the MvaSA110G
as the HMG-CoA synthase to further improve the produc-

































Figure 3 (See legend on next page.)
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Figure 3 GC-MS analysis of isoprenol and prenol in the cultures. By comparing with the authoritative isoprenol (a, e) and prenol (b, f), the
capacities of isoprenol and prenol biosynthesis were verified in the engineered strains YY159 and YY168, respectively. YY159 produced the
isoprenol as its single product (c, g), while YY168 produced a blend of isoprenol and prenol, with prenol as the dominant component (d, h). a, b,
c, d, total ion chromatogram (TIC); e, f, g, h, mass spectrum.
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http://www.biotechnologyforbiofuels.com/content/6/1/57the MvaSA110G (ISP214m) only produced 1.23 g/L me-
valonate, decreased by 25.5% when compared with the
strain carrying MvaS (ISP214) (Figure 5a). The reduced
supply of mevalonate directly led to the decreased output
of isoprenol and prenol. The isoprenol and prenol pro-
duction decreased to 0.7 g/L (YY159m) and 0.08 g/L
(YY168m), respectively (Figure 5b; 5c). It is surprising that
the accelerated reaction rate of MvaS did not enhance the
production of both mevalonate and isopentenols. A future
metabolic flux analysis will make this conversion process
clearer.
Evaluation of the isopentenol production of two
optimized strains
Thus far, YY159 and YY168 are the best-performed
strains for the production of isoprenol and prenol, re-
spectively. To better understand their isopentenol pro-
duction, we determined their product titers and yields in
specified periods of time. YY159 and YY168 shared a
similar process in the production of isopentenols. They
both reached their highest isopentenol titers approxi-
mately 32 h post-induction (Figure 6a; 6b). The linear
isoprenol productivity of YY159 and prenol productivity
of YY168 appeared approximately 4 ~ 8 h post-induction,
constant at 59.3 mg/L/h and 9.2 mg/L/h, respectively. InFigure 4 Isopentenol production by employing different
pyrophosphatases of E. coli except ADP-ribose
pyrophosphatase. Control, ISP2148 strain; nudC, strain expressing
NADH pyrophosphatase; yggV, strain expressing dITP/XTP
pyrophosphatase; lpxH, strain expressing UDP-2,3-diacylglucosamine
pyrophosphatase; hisl, strain expressing phosphoribosyl-ATP
pyrophosphatase; ppa, strain expressing inorganic pyrophosphatase;
cdh, strain expressing CDP-diacylglycerol pyrophosphatase.addition, the maximal isopentenol yield of 12% (i.e. 0.12 g
isopentenols/g glucose consumed) was observed in both
YY159 and YY168 (Figure 6c; 6d).
Discussion
In this study, we present a microbial system for high-
specificity production of isoprenol and prenol, two
promising new generation of biofuels, from sugar feed-
stocks. It mainly employs the MVA pathway that is used
for isoprenoid biosynthesis in nature [7,8], and finally di-
rects the IPP or DMAPP intermediate to pyrophosphate
hydrolization pathway for the production of isoprenol or
prenol. This endeavor met with several major challenges:
the construction of an efficient MVA pathway to IPP
and DMAPP from central metabolic intermediates, the
exploration of phosphatases or pyrophosphatases with
appropriate substrate specificities, and the engineering
of the host E. coli metabolism to selectively channel car-
bon flux and energy into isoprenol or prenol biosyn-
thetic pathway. The challenges met here are likely to be
characteristic for high-specificity production of any iso-
mers or homologues biologically, as these compounds
are quite similar in structure. Our provided approaches
to these problems may contribute to biocatalytic produc-
tion of more challenging relevant targets.
Our success in respectively producing over 1.3 g/L single
isoprenol and 0.2 g/L ~80% prenol from two engineered E.
coli strains demonstrates this strategy is promising for the
production of next generation of biofuels. Though it is still
needed to further improve the production of the isoprenol
and prenol by detailed optimization of the isopentenol bio-
synthetic pathways, our results are encouraging from sev-
eral standpoints.
First, we achieved the production of isoprenol and
prenol with high specificity. To our knowledge, this is
the first successful report on high-specificity production
of isoprenol and prenol from renewable sugar.
Second, we constructed and expressed an efficient
isopentenol biosynthetic pathway. Over 1.3 g/L isoprenol
achieved in lab-scale shake-flask experiments is a quite
encouraging isopentenol titer, demonstrating that this
strategy is promising for the commercial production of
higher-alcohol biofuels.
Third, we found that the ADP-ribose pyrophosphatase
from different organism had varied substrate preferences
towards IPP and DMAPP. In earlier study, no attention
was paid to the substrate specificity of ADP-ribose
pyrophosphatase. Our finding opens the door to tailoring
Figure 5 The effect of a mutated HMG-CoA synthase (MvaSA110G) on the production of mevalonate, isoprenol and prenol. The strain
employing MvaSA110G (ISP214m) produced a lower titer of mevalonate than the strain carrying the native enzyme MvaS (ISP214) (a). And in the
meanwhile, the decreased production of isoprenol (b) or prenol (c) was respectively obtained in two strains expressing the MvaSA110G (YY159
and YY168). The error bars represent the range from two independent experiments.
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pyrophosphatase. Developing pyrophosphatase with higher
hydrolyzing efficiency and specificity may contribute to a
further improvement of the isopentenol production.
Fourth, the yield of 12% achieved in shake flask was
observed during the post-induction, linear isopentenol
production period. This is a rather high yield, even slightly
higher than the well developed 3-methyl-1-butanol pro-
duction [6]. A further yield improvement will be obtained
under controlled conditions by using a scalable fermenta-
tion system.
Our data also suggests that mevalonate is an important
metabolite in determining the production of isoprenol,
given that over 80% mevalonate can be converted to
isoprenol. It provides another clue to further increase the
production of isoprenol.
Compared with the isoprenol production, a much
lower titer of prenol was obtained. The lower biomass
probably resulted in the decreased prenol production,
given the prenol producing strain (YY168) did not grow
so well as the strain for isoprenol synthesis (YY159).
Though YY168 finally obtained a higher biomass than
YY159, YY168 had lower biomasses during the period
when the isopentenols were largely produced (Figure 6).
To check if the products prenol and isoprenol inhibit
the normal growth of E. coli, we measured the growth of
E. coli BL21(DE3) in media supplemented with increas-
ing concentrations of exogenous prenol or isoprenol. A
slight growth inhibition was indeed observed in the
presence of prenol, but the inhibitory effect of prenol on
the growth of E. coli was even weaker than that ofisoprenol (Figure 7). Moreover, the strain YY168 pro-
duced a much lower product titer than YY159, which
grew well during the production of isoprenol. Therefore,
the growth inhibition of strain YY168 was not caused by
the synthesized prenol.
Martin et al. found that, using mevalonate as sub-
strate, the expression of partial MVA lower pathway
(MK, MKK and MVD) resulted in the highest concen-
tration of IPP, the expression of entire MVA lower path-
way (MK, MKK, MVD and IDI) led to a decreased
concentration of IPP, and the expression of an additional
synthetic pathway that converts IPP and DMAPP to
other metabolites further decreased the intracellular
concentration of IPP [7]. That is to say, IPP will largely
accumulate in engineered E. coli if it can’t be efficiently
converted to other metabolites. In the meanwhile, com-
pared to BsNudF, EcNudF has a much poorer substrate
specificity towards IPP, making IPP can’t be efficiently
hydrolyzed. Therefore, the lower cell density of YY168
may be attributed to the accumulation of IPP, which is
toxic and can inhibit normal cell growth [7].
Conclusions
The engineering strategy described above inaugurates a
new realm for the production of alcoholic biofuels. The
substrate specificities of ADP-ribose pyrophosphatases
were determined and successfully applied for the high-
specificity synthesis of isoprenol and prenol. The desired
isoprenol and prenol were finally produced with high speci-
ficities, being the first successful report on high-specificity
production of isoprenol and prenol from renewable sugar.
Figure 6 Characterization of isopentenol production of two best-performed strains YY159 and YY168. YY159, expressing
pyrophosphatase BsNudF and the whole MVA pathway except IDI1; YY168, expressing pyrophosphatase EcNudF and the whole MVA
pathway. YY159 produced a single isoprenol, while YY168 produced a major prenol. a, the isoprenol titer and growth curve of YY159; b, the
isopentenol titers and growth curve of YY168; c, the isoprenol yield of YY159; d, the isopentenol yield of YY168.
Zheng et al. Biotechnology for Biofuels 2013, 6:57 Page 8 of 13
http://www.biotechnologyforbiofuels.com/content/6/1/57The achieved over 1.3 g/L isoprenol represents an encou-
raging isopentenol titer. In addition, the isopentenols can
be isolated with the well-developed butanol recovery
techniques, such as gas stripping. Therefore, this strategy
provides the potential and possibility for scale-up produc-
tion of isopentenols by utilizing the butanol production
line without too much reconstruction. Altogether, thisFigure 7 The inhibitory effect of isoprenol and prenol on the
growth of E. coli. The E. coli BL21(DE3) was cultured at 37°C in
media supplemented with increasing concentrations of exogenous
prenol or isoprenol. OD600nm, optical density at 600 nm.work presents a promising strategy for high-specificity




The HMGS [Genbank: NM_001182489] was polymerase
chain reaction (PCR)-amplified from genomic DNA of S.
cerevisiae (ATCC 204508) with the primer set HMGS-F
and HMGS-R. The PCR product digested with NdeI and
XhoI was cloned into pACYCDuet-1 (Novagen, Darm-
stadt, Germany) cut with the same restriction enzymes,
creating pISP211. The tHMGR (a truncated version of
HMGR) was PCR-amplified from genomic DNA of S.
cerevisiae (ATCC 204508) with the primer set tHMGR-F
and tHMGR-R [7,12]. The PCR product digested with
NcoI and BamHI was cloned into pISP211 cut with the
same restriction enzymes, creating pISP212.
The mvaE [Genbank: AF290092] was PCR-amplified
from genomic DNA of Enterococcus faecalis (ATCC
700802D-5) with the primer set mvaE-F and mvaE-R.
The PCR product digested with NcoI and BamHI was
cloned into pACYCDuet-1 cut with the same restriction
enzymes, creating pISP213. The mvaS [Genbank:
AF290092] was PCR-amplified from genomic DNA of E.
faecalis (ATCC 700802D-5) with the primer set mvaS-F
and mvaS-R. The PCR product digested with SacI and
Table 1 Bacterial strains and plasmids used in this study
Plasmid or strain Relevant genotype or description Reference
Plasmids
pACYCDuet-1 P15A origin; CmR; PT7 Novagen
pTrcHis2B ColE1 origin; AmpR; Ptrc Invitrogen
pCOLADuet-1 ColA origin; KanR; PT7 Novagen
pISP212 P15A origin; CmR; PT7::HMGS(Sc)-tHMGR(Sc) This study
pISP214 P15A origin; CmR; PT7::mvaS(Ef)-mvaE(Ef) This study
pISP214m P15A origin; CmR; PT7::mvaSA110G-mvaE(Ef) This study
pTrcLower ColE1 origin; AmpR; Ptrc:: ERG12(Sc)-ERG8(Sc)-ERG19(Sc)-IDI1(Sc) [19]
pISP9 ColE1 origin; AmpR; Ptrc:: ERG12(Sc)-ERG8(Sc)-ERG19(Sc) This study
pYY11 ColA origin; KanR; PT7:: ‘phoA This study
pYY12 ColA origin; KanR; PT7:: ‘DPP1 This study
pYY13 ColA origin; KanR; PT7:: ‘LPP1 This study
pYY14 ColA origin; KanR; PT7:: phoE This study
pYY15 ColA origin; KanR; PT7::BsNudF This study
pYY16 ColA origin; KanR; PT7::EcNudF This study
pYY26 ColA origin; KanR; PT7::NudC This study
pYY36 ColA origin; KanR; PT7::yggV This study
pYY46 ColA origin; KanR; PT7::hisl This study
pYY56 ColA origin; KanR; PT7::lpxH This study
pYY66 ColA origin; KanR; PT7::ppa This study
pYY76 ColA origin; KanR; PT7::cdh This study
Strains
DH5α deoR, recA1, endA1, hsdR17(rk-,mk+), phoA, supE44, λ-, thi-1, gyrA96, relA1 Takara
BL21(DE3) E. coli B dcm ompT hsdS(rB
-mB
- ) gal Invitrogen
W 3110 F- λ- rph-1 INV(rrnD, rrnE) [24]
DNF(DE3) W3110: ΔEcNudF(DE3) This study
DNFYV(DE3) W3110: ΔEcNudFΔyggV(DE3) This study
ISP212 BL21(DE3) harboring pISP212 This study
ISP214 BL21(DE3) harboring pISP214 This study
ISP214m BL21(DE3) harboring pISP214m This study
ISP2148 BL21(DE3) harboring pISP214 and pTrcLower This study
ISP2149 BL21(DE3) harboring pISP214 and pISP9 This study
YY118 BL21(DE3) harboring pISP214, pTrcLower and pYY11 This study
YY128 BL21(DE3) harboring pISP214, pTrcLower and pYY12 This study
YY138 BL21(DE3) harboring pISP214, pTrcLower and pYY13 This study
YY148 BL21(DE3) harboring pISP214, pTrcLower and pYY14 This study
YY158 BL21(DE3) harboring pISP214, pTrcLower and pYY15 This study
YY168 BL21(DE3) harboring pISP214, pTrcLower and pYY16 This study
YY119 BL21(DE3) harboring pISP214, pISP9 and pYY11 This study
YY129 BL21(DE3) harboring pISP214, pISP9 and pYY12 This study
YY139 BL21(DE3) harboring pISP214, pISP9 and pYY13 This study
YY149 BL21(DE3) harboring pISP214, pISP9 and pYY14 This study
YY159 BL21(DE3) harboring pISP214, pISP9 and pYY15 This study
YY169 BL21(DE3) harboring pISP214, pISP9 and pYY16 This study
Zheng et al. Biotechnology for Biofuels 2013, 6:57 Page 9 of 13
http://www.biotechnologyforbiofuels.com/content/6/1/57
Table 1 Bacterial strains and plasmids used in this study (Continued)
YY159m BL21(DE3) harboring pISP214m, pISP9 and pYY15 This study
YY168m BL21(DE3) harboring pISP214m, pTrcLower and pYY16 This study
YY268 BL21(DE3) harboring pISP214, pTrcLower and pYY26 This study
YY368 BL21(DE3) harboring pISP214, pTrcLower and pYY36 This study
YY468 BL21(DE3) harboring pISP214, pTrcLower and pYY46 This study
YY568 BL21(DE3) harboring pISP214, pTrcLower and pYY56 This study
YY668 BL21(DE3) harboring pISP214, pTrcLower and pYY66 This study
YY768 BL21(DE3) harboring pISP214, pTrcLower and pYY76 This study
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tion enzymes, creating pISP214.
The ERG12, ERG8, ERG19 and IDI1 genes from S.
cerevisiae (ATCC 204508) were cloned into pTrcHis2B
(Invitrogen, Carlsbad, CA) using a method of successive
hybridization to yield pTrcLower [19].
To delete the IDI1 gene from pTrcLower, a fragment
containing ERG19, ERG8 and a part of ERG12 was first
PCR-amplified from pTrcLower with the primers
IDIKO-F and IDIKO-R, then digested with BamHI and
PstI, and finally cloned into the pTrcLower cut with the
same restriction enzymes. The resultant recombinant
plasmid designated pISP9.
The ‘phoA (a leaderless version of phoA [Genbank:
NC_000913.2:400971..402386]) was PCR-amplified from
genomic DNA of E. coli K12 with the primer set phoA-
F2 and phoA-R. The PCR product digested with BglII
and XhoI was cloned into pCOLADuet-1 (Novagen,
Darmstadt, Germany) cut with the same restriction en-
zymes, creating pYY11.
The ‘DPP1 (a leaderless version of DPP1 [Genbank:
NM_001180592]) was PCR-amplified from genomic
DNA of S. cerevisiae (ATCC 204508) with the primer set
DPP1-F2 and DPP1-R. The PCR product digested with
BglII and XhoI was cloned into pCOLADuet-1 cut with
the same restriction enzymes, creating pYY12.
The ‘LPP1 (a leaderless version of LPP1 [Genbank:
NM_001180811]) was PCR-amplified from genomic DNA
of S. cerevisiae (ATCC 204508) with the primer set LPP1-
F2 and LPP1-R. The PCR product digested with BglII and
XhoI was cloned into pCOLADuet-1 cut with the same
restriction enzymes, creating pYY13.
The phoE [Genbank: AL009126] was PCR-amplified
from genomic DNA of Bacillus subtilis (ATCC 23857)
with the primer set phoE-F and phoE-R. The PCR pro-
duct digested with BglII and XhoI was cloned into
pCOLADuet-1 cut with the same restriction enzymes,
creating pYY14.
The BsNudF [Genbank: AL009126] was PCR-amplified
from genomic DNA of B. subtilis (ATCC 23857) with
the primer set BsNudF-F and BsNudF-R. The PCR pro-
duct digested with NcoI and BamHI was cloned intopCOLADuet-1 cut with the same restriction enzymes,
creating pYY15.
The EcNudF [Genbank: NC_010473.1:3273048..3273677]
was PCR-amplified from genomic DNA of E. coli K12 with
the primer set EcNudF-F and EcNudF-R. The PCR product
digested with NcoI and BamHI was cloned into
pCOLADuet-1 cut with the same restriction enzymes,
creating pYY16.
The nudC, yggV, hisl, lpxH, ppa and cdh were PCR-
amplified from genomic DNA of E. coli K12 with the pri-
mer set nudC-F/nudC-R, yggV-F/yggV-R, hisl-F/hisl-R,
lpxH-F/lpxH-R, ppa-F/ppa-R and cdh-F/cdh-R, respect-
ively. The PCR products digested with NcoI and BamHI
were cloned into pCOLADuet-1 cut with the same restric-
tion enzymes, creating pYY26, pYY36, pYY46, pYY56,
pYY66 and pYY76, respectively.
All the plasmids and strains used in this work are
listed in Table 1, and the oligonucleotide primers are
given in Table 2.
Site-directed mutagenesis
A method based on the amplification of the entire plas-
mid using primers that include the desired changes was
employed for the site-directed mutagenesis [25]. The
Ala-110 of HMG-CoA synthase MvaS was mutated to
Gly by replacing a nucleotide C with G using the mutant
primers A110G-F and A110G-R.
The PrimeSTAR HS DNA polymerase (Takara) was
used for PCR. The PCR conditions were as follows: 98°C
for 30 sec; 12 × (98°C for 5 sec; 63°C for 5 sec; 72°C for
8 min); 72°C for 10 min. The mutant was verified by se-
quencing (BGI).
Gene knockout and λDE3 lysogenization
The EcNudF gene of E. coli was knocked out using the
one-step inactivation method previously reported [26].
This method includes following steps: amplification of
the kanamycin-resistant (KanR) gene with PCR using
pKD4 as template. The PCR product was transformed
into the cells by electro-poration after gel purification.
Transformants were selected with kanamycin-resistance
plate. The mutant was verified by PCR using the test
Table 2 Primers used in this study




















































Underlines indicate restriction enzyme sites.
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sette was removed with the helper plasmid pCP20 that
expresses FLP. The E. coli DNF was finally obtained after
removing the helper plasmids.
To express target genes cloned in vectors under the
control of the T7 promoter, λDE3 prophage was integrated
into the E. coli DNF chromosome using the λDE3 lysoge-
nization kit (Novagen, Darmstadt, Germany) according to
the manufacturer’s instructions. The obtained strain was
designated as E. coli DNF (DE3). The yggV gene was then
deleted with the same method using E. coli DNF (DE3) as
the starting strain. The resultant double-gene knockout
mutant was designated as E. coli DNFYV (DE3).
Bacterial strains, media and growth conditions
The bacterial strains used in this study are listed in Table 1.
E. coli BL21(DE3) (Invitrogen, Carlsbad, CA) was used as
the host to overproduce proteins. During strain construc-
tion, cultures were grown aerobically at 37°C in Luria
Broth (10 g/L tryptone, 10 g/L NaCl, and 5 g/L yeast
extract). Kanamycin (50 mg/L), Ampicillin (100 mg/L) or
chloramphenicol (34 mg/L) was added if necessary. For
initial production experiments in shake flasks, strains were
grown in a medium consisted of the following: 7.5 g/L
K2HPO4 · 3H2O, 2.1 g/L citric acid monohydrate, 0.3 g/L
ferric ammonium citrate, 2.92 g/L (NH4)2SO4, 30 g/L of
glucose, 9 g/L beef extract, 4 mM MgSO4, trace metals
mix (2.86 mg/L H3BO3, 1.81 mg/L MnCl2 · 4H2O,
0.222 mg/L ZnSO4 · 7H2O, 0.39 mg/L Na2MoO4 · 2H2O,
0.079 mg/L CuSO4 · 5H2O, 49.4 μg/L Co(NO3)2 · 6H2O).
The residual glucose was measured by the SBA-40D
Biosensor equipped with glucose oxidase membrane elec-
trodes (Shandong Academy of Sciences, Jinan, China).
Protein production was induced with 0.5 mM isopropyl β-
D-thiogalactoside (IPTG) at 30°C.
Determination of mevalonate
Ten milliliter cell free cultures were collected, adjusted
to pH 2.0 using hydrochloric acid, and incubated at 45°C
for 1 hour. Then 5 g of anhydrous granular sodium
sulphate was added to each vial followed by 10 ml of ethyl
acetate. The vials were mixed on a vortexer for 5 min and
the phases were allowed to separate naturally. One milli-
liter supernatant was collected for gas chromatograph
(GC) analysis. The separation of mevolonatone lactone
was performed using a CP-FFAP CB capillary column
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from Agilent Technologies (Santa Clara, CA). The oven
temperature was initially held at 150°C for 1 min, then
raised with a gradient of 10°C/min until reaching 250°C,
and finally held at 250°C for 10 min. Nitrogen was used as
the carrier gas. The injector and detector were held at
250°C and 270°C, respectively.
Analysis of isoprenol and prenol by GC-MS
Isoprenol and prenol produced by the engineered strains
were identified by GC–MS. The system consisted of model
7890A network GC system (Agilent Technologies) and a
model 5975C network mass selective detector (Agilent
Technologies, Santa Clara, CA). A HP-INNOWAX capil-
lary column (30 m× 0.25 mm; 0.25 μm film thickness;
Agilent Technologies) was used, with helium as the carrier
gas. The following oven temperature program was carried
out: 100°C for 1 min, increase of 5°C/min to 100°C, then
programmed from 100°C to 200°C at 25°C/min. The in-
jector was maintained at 250°C. Alcohol compounds were
isolated by ethyl acetate extraction. A 1 μl sample was
injected in split injection mode with a 20:1 split ratio.
Analysis of isoprenol and prenol by GC–FID
The produced isoprenol and prenol were quantified by a
GC equipped with flame ionization detector (FID). The
separation of isoprenol and prenol was performed using a
CP-FFAP CB capillary column (25 m × 0.25 mm; 0.2 μm
film thickness) purchased from Agilent Technologies
(Santa Clara, CA). The oven temperature was initially held
at 50°C for 1 min, then raised with a gradient of 5°C/min
until reaching 100°C, and finally programmed to 150°C at
25°C/min. Nitrogen was used as the carrier gas. The in-
jector and detector were held at 250°C and 270°C, respec-
tively. Samples were prepared by ethyl acetate extraction.
Isoamyl alcohol was added into the samples as the internal
standard before solvent extraction.
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